{"id":895,"date":"2024-09-11T16:17:35","date_gmt":"2024-09-11T08:17:35","guid":{"rendered":"https:\/\/flcube.com\/?p=895"},"modified":"2025-01-06T18:15:02","modified_gmt":"2025-01-06T10:15:02","slug":"abbvie-accuses-beigene-of-trade-secret-theft-in-btk-degrader-dispute","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=895","title":{"rendered":"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute"},"content":{"rendered":"\n

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader Program<\/strong>
U.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (<\/a>NASDAQ: BGNE<\/a>; HKG: 6160<\/a>; SHA: 688235<\/a>), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton’s tyrosine kinase (BTK) degrader program. According to court documents filed with the U.S. District Court for the Northern District of Illinois and reported by Reuters, AbbVie asserts that BeiGene lured and persuaded former AbbVie researcher Liu Huaqing to defect, subsequently utilizing proprietary information to expedite BeiGene’s BTK degrader initiative. Liu, who is implicated in the lawsuit, had previously contributed to AbbVie’s degrader program for approximately one year before his departure in 2019.<\/p>\n\n\n\n

BeiGene Fires Back at AbbVie’s Allegations, Vows to Defend IP Rights<\/strong>
In a recent statement, BeiGene has refuted the allegations, pledging to robustly safeguard its intellectual property against the legal challenge. The company suggests that the lawsuit is an attempt to impede the progress of its BTK degrader, BGB-16673. BeiGene also highlighted that it had filed for patents on BGB-16673 prior to AbbVie’s own patent application for a similar degrader.<\/p>\n\n\n\n

BGB-16673: A Promising BTK Degrader in Clinical Trials<\/strong>
BeiGene’s BTK degrader, BGB-16673, is a novel heterobifunctional small molecule designed to bind BTK and an E3 ligase, leading to BTK degradation and potentially overcoming resistance to conventional BTK inhibitors. The drug successfully concluded its first-in-human trial in November 2023 and is currently undergoing Phase I\/II trials in both China and the U.S.<\/p>\n\n\n\n

AbbVie’s Repeated Legal Offense Against BeiGene<\/strong>
This is the second instance within a year where AbbVie has taken legal action against BeiGene. In June 2023, AbbVie claimed that BeiGene’s BTK inhibitor, Brukinsa (zanubrutinib), infringed upon the patent rights of its own pioneering BTK inhibitor, Imbruvica (ibrutinib). – Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

AbbVie Sues BeiGene Over Alleged Trade Secret Theft in BTK Degrader ProgramU.S. pharmaceutical titan AbbVie…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11,61],"tags":[234,185,2092,847,846,3046,848,70],"class_list":["post-895","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","category-legal-ip","tag-abbvie","tag-beigene","tag-beone-medicines","tag-hkg-6160","tag-nasdaq-bgne","tag-nasdaq-onc","tag-sha-688235","tag-tpd"],"yoast_head":"\nAbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"U.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (HKG: 6160), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton's tyrosine kinase (BTK) degrader program.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=895\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=895\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-11T08:17:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:15:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=895#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=895\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute\",\"datePublished\":\"2024-09-11T08:17:35+00:00\",\"dateModified\":\"2025-01-06T10:15:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=895\"},\"wordCount\":314,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AbbVie\",\"BeiGene\",\"BeOne Medicines\",\"HKG: 6160\",\"NASDAQ: BGNE\",\"NASDAQ: ONC\",\"SHA: 688235\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\",\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=895#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=895\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=895\",\"name\":\"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-09-11T08:17:35+00:00\",\"dateModified\":\"2025-01-06T10:15:02+00:00\",\"description\":\"U.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (HKG: 6160), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton's tyrosine kinase (BTK) degrader program.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=895#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=895\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=895#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute - Insight, China's Pharmaceutical Industry","description":"U.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (HKG: 6160), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton's tyrosine kinase (BTK) degrader program.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=895","og_locale":"en_US","og_type":"article","og_title":"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=895","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-09-11T08:17:35+00:00","article_modified_time":"2025-01-06T10:15:02+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=895#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=895"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute","datePublished":"2024-09-11T08:17:35+00:00","dateModified":"2025-01-06T10:15:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=895"},"wordCount":314,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AbbVie","BeiGene","BeOne Medicines","HKG: 6160","NASDAQ: BGNE","NASDAQ: ONC","SHA: 688235","TPD"],"articleSection":["Company","Drug","Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=895#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=895","url":"https:\/\/flcube.com\/?p=895","name":"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-09-11T08:17:35+00:00","dateModified":"2025-01-06T10:15:02+00:00","description":"U.S. pharmaceutical titan AbbVie Inc. (ABBV) has initiated legal proceedings against BeiGene Ltd. (HKG: 6160), accusing the Chinese biotech firm of pilfering trade secrets vital to its Bruton's tyrosine kinase (BTK) degrader program.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=895#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=895"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=895#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie Accuses BeiGene of Trade Secret Theft in BTK Degrader Dispute"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=895"}],"version-history":[{"count":5,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/895\/revisions"}],"predecessor-version":[{"id":5717,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/895\/revisions\/5717"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}